I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for a free trial to Growth Stock Forum.Shares of TransMedics (NASDAQ: TMDX ) are down 60% from their August pea ...

Shares of leading organ transplant platform TransMedics (TMDX -15.65%) were down 14% as of noon ET on Wednesday, according to data provided by S&P Global Market Intelligence.TransMedics issued a positive news release yesterday evening about the hiring of Gerardo Hernandez as its new chief financial officer, but one sentence at the end of the announcement seemed to spook the market.TransMedics' tempered expectationsThis final sentence reads, "TransMedics now expects revenue for the full year 2024 to be in th ...

ANDOVER, Mass., Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024. In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon. To enable a smooth transition, Mr. Gordon ...

TransMedics Group (TMDX) is a key player in transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The company offers Organ Care System, an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation. However, with a forward 12-month price-to-sales (P/E) ratio of 5.02X — above the Zacks Medical - Instruments industry average of 4.44X — there are concerns about the justification of TransMedics’ premium valuation in t ...

ANDOVER, Mass., Nov. 26, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that it will host an Investor & Analyst Day in New York City on Tuesday, December 10, 2024, at 10:00 AM ET.Waleed Hassanein, MD., President and Chief Executive Officer, and members of the leadership team will present an overview of TransMedics' growth strateg ...

This growth stock has been on my watchlist for a while and might soon be included in my portfolio.In this video, I will talk about recent updates regarding TransMedics (TMDX 3.34%). Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of Nov. 22, 2024. The video was published on Nov. 24, 2024. ...

ANDOVER, Mass., Nov. 19, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace. The fireside chat will take place on Tuesday, December 3, 2024, at 4:00 p.m. Eastern Time.Eve ...

TransMedics Group, Inc. (NASDAQ: TMDX ) is quite a popular stock currently due to its incredible (good and bad) stock volatility. The stock rallied 300% over a 1-year period to then fall back to around 50% post Q3 earnings due to a small revenue missMMMT Wealth is run by Oliver, a CPA working in the financial services sector mainly in private equity, hedge funds, and asset management. MMMT Wealth began in 2023 when Oliver started writing online mainly on X and Substack about investment strategies and stocks ...

This organ transplant specialist is down, but still has plenty of signs of life.TransMedics Group (TMDX -4.71%) has emerged as a medical devices industry leader, capturing strong growth and climbing profitability from its organ transplant delivery system. Since the company's 2019 initial public offering, the stock has returned a massive 285%.That said, the early success hasn't been achieved without some stumbling blocks. The company's latest quarterly update came in below Wall Street estimates, and shares a ...

TransMedics' (NASDAQ: TMDX ) third quarter results were soft, with revenue declining sequentially. I previously suggested that new indications and geographies would be necessary for TransMedics to maintain a high-growth rate. I continue to believe that this is theRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be achieved b ...